Glucose 5 % "Fresenius" - Infusionslösung clinical trials

A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis

This study is testing a new medicine, TOL2, for generalised myasthenia gravis. It's looking at how safe the medicine is, how well people can tolerate it, and if it affects the body's immune system. This is an early-stage UK trial.